Man Wang

Man Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JZJinghan Zeng
Jinghan Zeng
YLYilu Liu
Yilu Liu
TZTianlang Zhao
Tianlang Zhao
JYJiansong Yuan
Jiansong Yuan
WYWeixian Yang
Weixian Yang
MWMan Wang
Man Wang
Objective: We aimed to conduct a meta-analysis of treatments for large vessel coronary artery disease between drug-coated balloons and drug-eluting stents. Method: We searched databases including PubMed, Web of Science, Cochrane, CNKI, and Wanfang, and selected randomized controlled trials (RCTs) or cohort studies which compared drug-coated balloons (DCBs) with drug-eluting stents (DESs). The reference vessel diameter (RVD) should be greater than 2.75 mm. The results of 12 studies with a total of 2634 patients were included in this meta-analysis. Results: The results showed that the DCB group was not inferior to the DES group in terms of the incidence of target lesion revascularization (TLR). (RR = 1.25, 95% CI: [0.84, 1.85], p = 0.27, I2 = 0%), and the incidence of bleeding events in the DCB group was lower than that in the DES group (RR = 0.30, 95% CI: [0.15, 0.59], p = 0.0004). The results also showed that the post-intervention minimal lumen diameter (MLD) in the DCB group was smaller than that in the DES group. (RR = −0.37, 95% CI: [−0.59, −0.16], p = 0.0007), but the follow-up MLD in the DCB group was not less than that in the DES group (RR = −0.03, 95% CI: [−0.14,−0.08], p = 0.61). Additionally the DCB group had less late lumen loss (LLL) compared with the DES group. (RR = −0.31, 95% CI: [−0.60, −0.02], p < 0.0001). Conclusion: This meta-analysis confirms that in the early and late stages after percutaneous coronary intervention (PCI), DCB is not inferior in efficacy and safety to DES for de novo large coronary lesions with RVD > 2.75 mm.

2 June 2026 in Oncology and Translational Medicine
Verified
Journal Article
Open access
YCYan Chen
Yan Chen
HLHongmei Liu
Hongmei Liu
MWMan Wang
Man Wang
LGLijian Gao
Lijian Gao
This comprehensive review examined the application of the distal transradial approach (dTRA) in percutaneous coronary intervention (PCI). The dTRA, characterized by its unique anatomical access site in the anatomical snuffbox, demonstrates distinct features for both puncture and hemostasis techniques. dTRA offers several advantages compared with conventional transradial access, including shorter hemostasis time, reduced incidence of access-site hematoma and compartment syndrome, lower rates of radial artery occlusion, enhanced patient and operator comfort, and a potential for retrograde recanalization of the occluded radial arteries. However, it also presents challenges, including a steeper learning curve, limitations related to a smaller arterial diameter, and constraints in patients with taller stature or specific anatomical variations. Clinically, dTRA has been used in diverse patient cohorts, including patients with acute coronary syndrome, those undergoing complex PCI procedures, and individuals with preexisting radial artery occlusion. Although ongoing clinical controversies exist regarding its universal adoption, these could be addressed through technical refinements, standardized training, and device innovations. Future directions include optimizing procedural protocols, expanding evidence from randomized trials, and exploring technological advancements to enhance feasibility. Overall, this review summarizes and evaluates the current evidence to provide a foundational reference for the broader implementation and further investigation of dTRA in PCI.